Cancer

January 23, 2014

Human and Helicobacter co-evolution

By VUMC News and Communications
January 21, 2014

VICC receives $100,000 ovarian cancer research grant

The Kay Yow Cancer Fund, in partnership with the Women’s Basketball Coaches Association and The V Foundation for Cancer Research, has awarded a $100,000 ovarian cancer research grant to the Vanderbilt-Ingram Cancer Center.

By VUMC News and Communications
January 21, 2014

Vanderbilt-Ingram Cancer Center receives $100,000 ovarian cancer research grant from Kay Yow Cancer Fund

By VUMC News and Communications
January 9, 2014

Pioneers of Discovery: Investigator seeks to debug cancer’s ‘bad software’

Beyond genetics — that’s the call Oliver McDonald, M.D., Ph.D., heard during the year between college and medical school he spent in a lab at St. Jude Children’s Research Hospital in Memphis.

By Bill Snyder
December 19, 2013

VU study identifies new gene fusions in melanoma

Cancer researchers, led by investigators at Vanderbilt-Ingram Cancer Center, have identified two novel gene fusions in melanoma that may be responsive to existing cancer therapies. Melanoma is the most deadly form of skin cancer.

By VUMC News and Communications
December 18, 2013

Targeting tumor “supply lines”

A metabolic enzyme plays a crucial role in vascular development and may be a good target for cancer therapies.

By Leigh MacMillan
December 16, 2013

Cancer drug enhances cognition

The breast cancer drug tamoxifen improves cognitive performance in post-menopausal women.
By Leigh MacMillan
December 12, 2013

Therapeutic target for gastric cancer

A protein kinase linked to inflammation and tumor development may be a good target for gastric cancer therapies.
By Leigh MacMillan
December 5, 2013

Predictor of prostate cancer outcomes identified

Researchers at Vanderbilt University Medical Center and the University of Alberta in Canada have identified a biomarker for a cellular switch that accurately predicts which prostate cancer patients are likely to have their cancer recur or spread.
By VUMC News and Communications
November 21, 2013

Therapeutic target for synovial sarcoma

Inhibitors of a signaling pathway that is critical to synovial sarcoma tumorigenesis may be useful treatments for this aggressive cancer.
By Leigh MacMillan
November 14, 2013

Family’s support enhances cancer research training

John F. Brock III, chairman and CEO of Coca-Cola Enterprises, his wife, Mary, and their three children have established an endowment to support an oncology fellowship at Vanderbilt-Ingram Cancer Center. The Brock Family Fellowship will provide financial assistance long into the future for young physicians, postdoctoral students and medical investigators who are furthering their training in cancer research.
By VUMC News and Communications
November 13, 2013

Molecular circuits in ovarian cancer

Vanderbilt researchers have used bioinformatics analysis of gene expression data to describe molecular “circuits” that drive ovarian cancer.
By Leigh MacMillan
November 7, 2013

VU study sheds new light on DNA replication

David Cortez, Ph.D., and his Vanderbilt colleagues report new findings that shed light on fundamental processes involved in DNA replication and have implications for cancer therapies that target these processes.
By Leigh MacMillan